Frontiers | RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy
Clinical data presented at the 2026 American Society of Clinical Oncology Annual Meeting showed a survival benefit with the multi‑selective RAS inhibitor daraxonrasib (RMC‑6236) in advanced pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Mutant KRAS is a major driver…
This demonstrates that targeting RAS can translate into clinically meaningful survival improvements in a disease that has historically had limited therapeutic options.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.